Andere Kunden interessierten sich auch für
![Overcoming Solubility Challenges: A Strategy for Improving Bioavailability of Poorly Soluble Drugs with Self-Emulsifying Drug Delivery Systems]( "Overcoming Solubility Challenges: A Strategy for Improving Bioavailability of Poorly Soluble Drugs with Self-Emulsifying Drug Delivery Systems")
Overcoming Solubility Challenges: A Strategy for Improving Bioavailability of Poorly Soluble Drugs with Self-Emulsifying Drug Delivery Systems26,99 €![Why Our Drug Laws Have Failed and What We Can Do about It: A Judicial Indictment of the War on Drugs]( "Why Our Drug Laws Have Failed and What We Can Do about It: A Judicial Indictment of the War on Drugs")
Why Our Drug Laws Have Failed and What We Can Do about It: A Judicial Indictment of the War on Drugs33,99 €![Bringing Your Pharmaceutical Drug to Market]( "Bringing Your Pharmaceutical Drug to Market")
Bringing Your Pharmaceutical Drug to Market144,99 €![An Introduction to Law and Regulation]( "An Introduction to Law and Regulation")
An Introduction to Law and Regulation83,99 €![Financial Report and Audited Statements of the United Nations Office on Drugs and Crime for the Biennium Ended 31 December 2011 and Report of the Boar]( "Financial Report and Audited Statements of the United Nations Office on Drugs and Crime for the Biennium Ended 31 December 2011 and Report of the Boar")
Financial Report and Audited Statements of the United Nations Office on Drugs and Crime for the Biennium Ended 31 December 2011 and Report of the Boar12,99 €![Examples & Explanations for Securities Regulation]( "Examples & Explanations for Securities Regulation")
Examples & Explanations for Securities Regulation77,99 €![Legal Aspects of Financial Services Regulation and the Concept of a Unified Regulator]( "Legal Aspects of Financial Services Regulation and the Concept of a Unified Regulator")
Legal Aspects of Financial Services Regulation and the Concept of a Unified Regulator34,99 €
Globalization in the pharmaceutical industry, expanded FDA authority over CGMPs, and increased scrutiny of data integrity, among other developments in this rapidly evolving field, make for a complex compliance environment. This resource provides the legal community and regulated industry with a concise reference on the compliance standards and governing principles for current Good Manufacturing Practices. Even as these standards will change over time, the underlying concepts discussed will help the reader understand these changes, and how to incorporate them into a robust compliance program. Table of Contents Introduction I. What Are CGMPs? A. Principles B. Legal Framework C. FDA Guidance to Industry II How Does FDA Evaluate CGMP Compliance? A. Establishment Inspections B. Samples C. Field Alert Reports D. Adverse Event Reports and Consumer Complaints E. Risk-Based Selection of Sites and Inspection Frequency/Rigor F. Regulation of CGMPs for OTC Monograph and Homeopathic Drugs III What Are the Consequences of Noncompliance? A. Advisory Actions: Warning Letters, Untitled Letters and Regulatory Meetings B. Import Detentions and Import Alerts C. Recalls D. Seizures E. Injunctions F. Criminal Prosecutions G. False Claims Act and Qui Tam Investigations H. Other Consequences I. Certificates of Export/Government Contracts J. Application Disapproval/Revocation K. Application Integrity Policy IV Recent CGMP Enforcement Activity A. The Pattern of Enforcement B. GlaxoSmithKline, PLC and its Subsidiary SB Pharmco Puerto Rico Inc. C. Genzyme Corporation D. Ranbaxy Laboratories Limited and its Subsidiary Ranbaxy USA Inc. V How Do We Remain "Current" with CGMPs?